Why the study?
Survivors of myocardial infarction face elevated long-term mortality, prompting evaluation of guideline-directed medical treatment and its impact across different chronic kidney disease stages.
Does guideline-directed medical treatment improve long-term mortality in survivors of STEMI across different stages of chronic kidney disease?
Does guideline-directed medical treatment improve long-term mortality in survivors of STEMI across different stages of chronic kidney disease?
Answers are grounded in this paper and cite their sources.
Guideline-directed medical therapy significantly improves long-term survival after STEMI across all stages of chronic kidney disease, though prescription rates remain suboptimal and decline over time, particularly in patients with severe renal impairment.
Background Survivors of myocardial infarction have an elevated risk of long-term mortality. We sought to evaluate guideline-directed medical treatment and its impact on long-term mortality in survivors of ST-elevation myocardial infarction (STEMI) according to their chronic kidney disease (CKD) stage. Methods Using German health insurance claims data, 157 663 hospitalized survivors of STEMI were identified. Regarding different CKD stages, we retrospectively analysed the filled prescriptions of platelet inhibitors (PAI)/oral anticoagulation, statins, beta-blocker and angiotensin-converting enzyme inhibitors/angiotensin II type 1 receptor antagonists (ACE-I/AT1-A) and their association with long-term mortality. Results Prescription rates for all four guideline-directed drugs were highest in patients without or with mild CKD and lowest in patients on dialysis. They dropped from 73.4% to 39.2% in patients without CKD and from 47.1% to 29% in patients on dialysis within the 5-year follow-up period. Mortality rates were dramatically increased in patients with CKD compared with patients without CKD (5-year mortality: no CKD, 16.7%; CKD stage 3, 47.1%; CKD stage 5d, 69.7%). Filled prescriptions of at least one drug class [one drug: hazard ratio (HR) 0.70, 95% confidence interval (95% CI) 0.66–0.74; four drugs: HR 0.28, 95% CI 0.27–0.30; P < .001 for both] as well as the distinct drug classes (statins: HR 0.55, 95% CI 0.54–0.56; ACE-I/AT1-A: HR 0.68, 95% CI 0.67–0.70; beta-blocker: HR 0.87, 95% CI 0.85–0.90; PAI/oral anticoagulation: HR 0.97, 95% CI 0.95–1.00; all P < .05) improved long-term mortality. Conclusions An improved long-term guideline-recommended drug therapy after STEMI regardless of renal impairment might lead to beneficial effects on long-term mortality.
No takes yet. Share an insight, caveat, or question.
Engelbertz et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: